Good Feedback for OMS721 Stem Cell Transplant Therapy

OMS721 Stem Cell Transplant Therapy
OMS721 Stem Cell Transplant Therapy

On 26 July 2018, Omeros Corporation announced that the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) have positively recommended the lead human monoclonal antibody named OMS721 for stem cell transplantation therapy.  

This antibody targets the effector enzyme named mannan-binding lectin-associated serine protease-2 (MASP-2). Around three OMS721 phase 3 clinical programs are continuing across immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (TMA), and atypical hemolytic uremic syndrome (aHUS).
This positive declaration will soon be adopted by the European Commission in August. The Orphan Drug Designation in Europe will be made available to the companies in order to treat chronically debilitating conditions. This designation allows for regulatory and financial incentives including 10 years of marketing exclusivity in the European Union after product approval, lessened EMA advisory, inspection and filing fees pre- and post-approval, and guaranteed access to centralized marketing authorization valid in EU member states and European Economic Area countries.
At first, the U.S. Food and Drug Administration granted orphan designation to OMS721 in order to prevent complement-mediated TMA and finally granted therapeutic designation to OMS721 for the stem cell transplant therapy. Still, the discussions are going on with U.S. and European regulators regarding OMS721 approval for "high-risk" stem cell transplant-associated TMA treatment.
The post Good Feedback for OMS721 Stem Cell Transplant Therapy appeared first on Drugdu.com
from Drugdu  https://goo.gl/QgQoHk

评论

发表评论

此博客中的热门博文

NuVasive gets FDA Approval for Pulse Spinal Surgical Automation Platform

图片
The San Diego-based company NuVasive has announced US-FDA 510(k) clearance for its Pulse spinal surgical automation platform. The platform includes 2D and 3D navigation and smart imaging capabilities, with implemented surgical planning, neuromonitoring, patient-specific rod bending tech and radiation reduction. Dr. Stephen Ryu of the Palo Alto Medical Foundation said,  “Pulse seamlessly integrates multiple intraoperative technologies through an intuitive guided surgical workflow within a single device and footprint in the operating room. Unlike other newer surgical technologies, Pulse enhances the surgeon’s ability and can positively affect outcomes by providing a modular platform of useful intraoperative tools that do not disrupt familiar workflow. Additionally, Pulse provides enhanced support throughout each case be it a simple decompression all the way to complex deformity cases.” The platform has been integrated with a ...
阅读全文

New Version of Fitbit, Charge 3, Features Spo2 Tracking

图片
A new member has been added to the Fitbit Charge Family namely the Fitbit Charge 3 with an additional feature of measuring the SpO2. The new version will hit the market in October.  “ With Charge 3, we are building on the success of our best-selling Charge franchise and delivering our most innovative tracker, offering an extremely slim, comfortable, and premium design, along with the advanced health and fitness features our users want. Charge 3 gives existing users a compelling reason to upgrade, while also allowing us to reach new users who want a sleeker, more affordable wearable in a tracker form factor ,” CEO Fitbit James Park said in a statement. The new version claims to identify indicators of allergies, asthma, or sleep apnea with its relative SpO2 tracker which enables the device to assess variations in blood oxygenation levels and spot breathing abnormalities. As included in its Pre-Cert pilot, aiming to develop FDA-monitored software for illnesses like sleep apne...
阅读全文

New Biomarker to Prevent Severe Bouts of Low Blood Sugar in Diabetics

图片
A new biomarker might possibly furnish new clues required to develop a diagnostic tool for hypoglycemia-associated autonomic failure (HAAF), an LSU Pennington Biomedical Research Center study found. There is no current objective diagnostic device for this life-threatening condition, if unchecked. "There is currently no objective way for a health care provider to measure whether a patient has experienced repeated episodes of low blood sugar and therefore may be suffering from HAAF," said David McDougal, Ph.D., assistant professor-research and head of Pennington Biomedical's Neurobiology of Metabolic Dysfunction Laboratory. Researchers at LSU Pennington Biomedical aimed to find ways via which biomedical imaging could present new solutions that enable measurement of occurrence of glucose level collapse. Instead of looking at glucose uptake in the directly in the brain, they focused on the adaptation of the brain after an incidence of crashed glucose leve...
阅读全文